FER vs OMEX Stock Comparison

Ferrovial and Odyssey Marine Exploration Prices as of Oct 27, 2026 Peers: Industry group
FER Ferrovial N.V.
$54.02 -3.2% 1M -16.7% 1Y
Market cap
$39.16B
P/E
38.7x
Revenue (TTM)
—
Div. yield
–
Engineering and Construction Industrials
5 wins

Head to Head

5 decided of 12

Ferrovial leads on 5 of the 12 questions below (Ferrovial 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionFEROMEXLeader
Larger companyMarket capitalisation $39.16B $30.66M FER
Cheaper on earningsLower P/E, profitable companies only 38.7x -0.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 50.5x — –
Faster revenue growthRevenue growth, trailing twelve months — -70.3% –
More profitableNet margin, trailing twelve months — -21,426.8% –
Better return on capitalReturn on invested capital — — –
Less leveragedLower net debt / EBITDA — -0.4x –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -16.7% -77.7% FER
Better 5-year returnAnnualised price return, 5 years +12.9%/yr -39.4%/yr FER
Less volatileAnnualised volatility, 1 year 26.3% 102.7% FER
Higher overall scoreMean of the five percentile scores vs peers 47/100 1/100 FER

Percentile Scorecard

FEROMEX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisFEROMEX
Valuation 35 #34 of 52 0 #52 of 52
Growth – 6 #35 of 37
Profitability – 0 #37 of 37
Financial Health 34 #38 of 57 2 #56 of 57
Shareholder Returns 73 #8 of 27 0 #27 of 27
Overall 47 1
  • FER ranked among 57 companies in Construction Services
  • OMEX ranked among 57 companies in Construction Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodFEROMEXSPY
1 month -3.2%-22.9% -0.2%
3 months -12.5%-19.4% +3.9%
6 months -20.4%-37.9% +8.2%
Year to date -16.4%-72.4% +12.9%
1 year -16.7%-77.7% +12.3%
3 years +66.2%-84.7% +87.4%
3 years, per year +18.5%-46.5% +23.3%
5 years +83.7%-91.8% +67.9%
5 years, per year +12.9%-39.4% +10.9%
10 years +155.1%-87.6% +261.1%
10 years, per year +9.8%-18.9% +13.7%

Risk

MeasureFEROMEXSPY
Volatility, 1Y 26.3%102.7% 12.7%
Downside volatility, 1Y 24.6%98.7% 12.7%
Beta vs S&P 500, 1Y 1.043.21 1.00
Return / volatility, 1Y -0.63-0.76 0.97
Max drawdown, 5Y -34.3%-95.8% -25.4%
From 52-week high -27.4%-77.7% -1.2%
52-week high $74.38$2.42 $779.14
52-week low $48.86$0.51 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleFEROMEX
P/E now vs peer median 38.7xmedian 26.7x -0.8xmedian 26.7x
P/S now vs peer median 3.6xmedian 0.8x 172.2xmedian 0.8x
EV/EBITDA now vs peer median —median 13.1x -2.0xmedian 13.1x
P/FCF now vs peer median 19.8xmedian 23.0x -2.4xmedian 23.0x
P/B now vs peer median 5.6xmedian 2.4x -0.4xmedian 2.4x
PEG now vs peer median —median 0.57 0.01median 0.57

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsFEROMEX
Revenue – $184.07K
Operating income – -$20.93M
Net income – -$40.17M
Free cash flow – -$13.44M
R&D – $2.89M
EPS (diluted) – $-0.67
Cash & equivalents $5.02B $2.35M
Total debt $12.25B $30.18M
Shares (diluted) 718.72M 58.59M
Enterprise value $17.41B $16.87M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricFEROMEX
P/E 38.7x -0.8x
P/FCF 19.8x -2.4x
P/Operating cash flow – -2.4x
P/S 3.6x 172.2x
P/B 5.6x -0.4x
P/Tangible book 5.7x -0.4x
EV/EBITDA – -2.0x
EV/EBIT – -1.9x
EV/Revenue – 213.4x
EV/FCF – -2.9x
EV/Operating cash flow – -2.9x
PEG (3Y EPS CAGR) – 0.01

Growth

14 metrics
MetricFEROMEX
Revenue growth (1Y) – -70.3%
Revenue CAGR (3Y) – -45.0%
Gross profit growth (1Y) – –
Gross profit CAGR (3Y) – –
Operating income growth (1Y) – -92.5%
Operating income CAGR (3Y) – -15.2%
Net income growth (1Y) – -372.5%
Net income CAGR (3Y) – -186.3%
EPS growth (1Y) – -2,016%
EPS CAGR (3Y) – -124.4%
Operating cash flow growth (1Y) – -84.9%
Operating cash flow CAGR (3Y) – 3.7%
Free cash flow growth (1Y) – -85.1%
Free cash flow CAGR (3Y) – 7.7%

Profitability

14 metrics
MetricFEROMEX
Gross margin – –
EBITDA margin – -10,771%
Operating margin – -11,370%
Pretax margin – -21,821%
Net margin – -21,427%
FCF margin – -7,299%
Operating cash flow margin – -7,290%
Return on equity – –
Return on assets – -301.6%
Return on invested capital – –
Return on capital employed – –
Asset turnover – 0.0x
Cash conversion (OCF / net income) – 0.3x
Stock comp / revenue – 228.9%

Financial Health

11 metrics
MetricFEROMEX
Debt / assets 38.0% 75.0%
Debt / equity 1.8x -0.1x
Net debt / EBITDA – -0.4x
Debt / FCF – -0.7x
Liabilities / assets 78.5% 703.9%
Equity / assets 21.5% -603.9%
Interest coverage – -7.2x
Current ratio 1.1x 0.1x
Quick ratio 1.1x 0.1x
Cash ratio 0.7x 0.1x
Altman Z-score – -42.18

Shareholder Returns

7 metrics
MetricFEROMEX
Dividend yield 1.4% –
Net buyback yield – -27.1%
Shareholder yield 1.4% -27.1%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusFEROMEX
Forward P/E 50.5xFY2026 –
EPS, next fiscal year $1.07FY2026 $-0.91FY2023
EPS growth, next FY -20.7%FY2026 –
EPS growth, the year after +12.1% –
Revenue, next fiscal year $11.77BFY2026 $979.70KFY2023
Revenue growth, next FY +4.1%FY2026 –
Revenue growth, the year after -5.3% +1.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersFEROMEX
Held by institutions 33.2% 41.7%
Institutions holding 337 61
Change in shares held, QoQ +17.5% +13.6%
Institutions buying 208 29
Institutions selling 103 11
Buyers to sellers 2.02 2.64

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

FEROMEX
FER 1.00 0.26
OMEX 0.26 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, FER and OMEX?

Ferrovial (FER) is the largest by market capitalisation: Ferrovial (FER) $39.16B, Odyssey Marine Exploration (OMEX) $30.66M.

Which stock has performed better?

Over the past year Ferrovial (FER) returned the most: Ferrovial (FER) -16.7%, Odyssey Marine Exploration (OMEX) -77.7%. Over five years, Ferrovial (FER) compounded fastest (Ferrovial (FER) +12.9%/yr, Odyssey Marine Exploration (OMEX) -39.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Ferrovial (FER) has been the steadiest (Ferrovial (FER) 26.3%, Odyssey Marine Exploration (OMEX) 102.7%). Volatility measures how widely the price swings, not the risk of the business.

Do FER and OMEX move together?

Their daily returns over the past year have a correlation of 0.26, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, FER and OMEX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Ferrovial (FER) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.